Staidson (Beijing) BioPharmaceuticals Co Ltd

Staidson (Beijing) BioPharmaceuticals Co Ltd has a current liquidity position that is characterized by a negative net cash position after subtracting total debt, indicating potential liquidity risk. The company's liquidity FPT (free cash flow to total debt) is not explicitly provided, but the negative operating and free cash flows of -125,682,090 CNY and -138,740,920 CNY, respectively, suggest a cash outflow that could strain its ability to meet short-term obligations. The current ratio of 1.44 indicates that the company has 1.44 CNY in current assets for every 1 CNY in current liabilities, which is slightly above the industry median but still suggests a moderate liquidity risk.

Profitability metrics for Staidson (Beijing) BioPharmaceuticals Co Ltd are weak, with a return on equity (ROE) of -9.47% and a return on assets (ROA) of -6.14%. These figures are significantly below the industry median for pharmaceutical companies, which typically have positive ROE and ROA values. The company reported a net loss of 77,763,330 CNY and an operating loss of 87,438,910 CNY, indicating that it is not currently generating sufficient revenue to cover its operating costs.

The company's revenue is not segmented by product or geographic region in the provided data, but the negative operating cash flow and free cash flow suggest that it is not generating sufficient cash from operations to fund its activities. The capital expenditure of -76,632,320 CNY indicates that the company is investing in long-term assets, but the negative value suggests that these investments are not yet generating positive returns.

Looking at the company's growth trajectory, the most recent actual revenue was 806,079,310 CNY, but the company is currently reporting a net loss. The outlook for the current fiscal year is not provided, but the negative operating and free cash flows suggest that the company may face challenges in achieving revenue growth in the near term.

The risk assessment for Staidson (Beijing) BioPharmaceuticals Co Ltd indicates a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio of 0.11 is relatively low, suggesting that it is not heavily leveraged. However, the negative net cash position after subtracting total debt is a red flag for liquidity. The company has not issued additional shares recently, and the dilution risk is low, but the negative cash flows could lead to future dilution if the company needs to raise capital.

Recent events and filings do not provide specific details on the company's operations or financial performance beyond the reported financials. The company's financial snapshot indicates a challenging operating environment, with significant losses and negative cash flows. The company may need to secure additional financing or reduce costs to improve its financial position.